Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PXL770 in NAFLD
NCT03950882Phase 1Completed
- Sponsor
- Poxel SA
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing PXL770 500 mg with Placebo (2 arms). Primary endpoint: PK parameters of PXL770 at Day 26. Started Aug 2019; status: completed.
02
Drugs
PXL770
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03950882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950882.